Corgenix and NIH in liver test pact:
This article was originally published in Clinica
Corgenix Medical has struck a deal with the US National Institutes of Health (NIH) to develop a test for the liver disease non-alcoholic steatohepatitis (NASH). The corporative research and development agreement (CRADA) will use Corgenix's hyaluronic acid (HA) test kit in combination with other liver fibrosis biomarkers to develop a test for NASH - a form of non-alcoholic fatty liver disease (NAFLD). Currently the only way to distinguish NASH from NAFLD is to run a highly invasive liver biopsy test; differentiating the two is important since the conditions have different prognoses, said the Denver, Colorado based company. Some 65-75 million Americans currently suffer from NAFLD.
You may also be interested in...
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.